Iteos Therapeutics Inc (ITOS) Stock Price, Quote & News

Company Profile

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cel...

Industry: Biotechnology

Sector: Healthcare

Phone: 339 217 0161

Website: www.iteostherapeutics.com

Address:

321 Arsenal Street, Watertown, United States

nico10 Jul. 11 at 4:26 PM

$ITOS is a big move coming? 11 calls for august are really cheap .

0 · Reply

joe77w Jun. 24 at 3:21 PM

$ITOS TANG with 9.99% https://www.otcmarkets.com/filing/html?id=18545810&guid=uNi-kpAMy8JjJth

0 · Reply

joe77w Jun. 24 at 3:20 PM

$ITOS Concentra in so I would not be surprised with a cash offer plus CVR, just speculation.

0 · Reply

Count__Stockula Jun. 23 at 4:21 AM

$ITOS hear the news last week? Annual shareholder meeting was held. More news coming this week. 😁

0 · Reply

Count__Stockula Jun. 14 at 12:59 PM

$ITOS news coming this week.

0 · Reply

bullwink Jun. 12 at 5:41 PM

$ITOS Is management going to do anything about strategic alterbatives and preserve shareholder capital or just smoke and mirror announcement weeks ago?

0 · Reply

Count__Stockula Jun. 11 at 6:22 AM

$ITOS should be asking whos been buying up shares and why.

0 · Reply

nico10 Jun. 10 at 9:51 AM

$ITOS insiders are selling big...

0 · Reply

nico10 Jun. 9 at 5:51 PM

$ITOS what is the future for this stock? In the last week it didnt moove

0 · Reply

Count__Stockula Jun. 3 at 5:49 PM

$ITOS news soon. Easy buy and wait. Some know and are keeping it to themselves.

0 · Reply

iTeos Therapeutics Announces Its Intention to Wind Down Operations

May 13, 2025, 7:55 AM EDT - 2 months ago

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Apr 28, 2025, 4:30 PM EDT - 2 months ago

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 25, 2025, 4:35 PM EDT - 3 months ago

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Mar 5, 2025, 7:00 AM EST - 4 months ago

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Feb 27, 2025, 11:00 AM EST - 4 months ago

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless

Dec 17, 2024, 7:01 PM EST - 7 months ago

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

Dec 12, 2024, 8:55 AM EST - 7 months ago

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

Nov 26, 2024, 7:00 AM EST - 8 months ago

iTeos to Participate in Upcoming Investor Conferences

Nov 12, 2024, 7:00 AM EST - 8 months ago

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 16, 2024, 8:44 AM EDT - 10 months ago

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

UPST

Sep 15, 2024, 3:37 AM EDT - 10 months ago

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 14, 2024, 2:30 AM EDT - 10 months ago

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Aug 20, 2024, 8:30 AM EDT - 11 months ago

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

Aug 5, 2024, 7:00 AM EDT - 1 year ago

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

Jul 8, 2024, 9:00 PM EDT - 1 year ago

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 8, 2024, 7:00 AM EDT - 1 year ago

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

Jun 17, 2024, 9:00 AM EDT - 1 year ago

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

May 10, 2024, 9:45 AM EDT - 1 year ago

iTeos Therapeutics to raise $120 million via registered direct offering

May 10, 2024, 8:26 AM EDT - 1 year ago

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:24 AM EDT - 1 year ago

iTeos Therapeutics Announces $120 Million Registered Direct Offering

Apr 7, 2024, 4:30 PM EDT - 1 year ago

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

Mar 6, 2024, 7:01 AM EST - 1 year ago

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

Mar 6, 2024, 7:00 AM EST - 1 year ago

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 4:30 PM EST - 1 year ago

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY CGEN GSK MRK NVS PFE

Nov 21, 2023, 7:00 AM EST - 1 year ago

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 4, 2023, 9:00 AM EDT - 1 year ago

iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail

Aug 25, 2023, 3:55 PM EDT - 2 years ago

iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall

Aug 23, 2023, 8:45 AM EDT - 2 years ago

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

GILD RCUS

Aug 8, 2023, 7:00 AM EDT - 2 years ago

iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 4, 2023, 10:04 AM EDT - 2 years ago

iTeos Therapeutics: Trading Under Cash Value

May 10, 2023, 7:01 AM EDT - 2 years ago

iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates

Mar 15, 2023, 7:00 AM EDT - 2 years ago

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 2, 2023, 2:41 PM EST - 2 years ago

iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through

Feb 28, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at Cowen 43rd Annual Health Care Conference

Feb 7, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at SVB Securities Global Biopharma Conference

Jan 9, 2023, 7:00 AM EST - 2 years ago

iTeos Provides Business Updates and Clinical Development Plans for 2023

Jan 3, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 2 years ago

iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 10, 2022, 4:01 PM EST - 2 years ago

iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates

Aug 10, 2022, 4:01 PM EDT - 3 years ago

iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022, 7:00 AM EDT - 3 years ago

iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

Jun 13, 2022, 4:39 AM EDT - 3 years ago

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

May 12, 2022, 4:01 PM EDT - 3 years ago

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

Apr 12, 2022, 2:00 AM EDT - 3 years ago

Innoskel Appoints Dr Michel Detheux as Chairman

Apr 8, 2022, 1:00 PM EDT - 3 years ago

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

Mar 23, 2022, 4:01 PM EDT - 3 years ago

iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Mar 1, 2022, 7:00 AM EST - 3 years ago

iTeos to Present at the Cowen 42nd Annual Health Care Conference

nico10 Jul. 11 at 4:26 PM

$ITOS is a big move coming? 11 calls for august are really cheap .

0 · Reply

joe77w Jun. 24 at 3:21 PM

$ITOS TANG with 9.99% https://www.otcmarkets.com/filing/html?id=18545810&guid=uNi-kpAMy8JjJth

0 · Reply

joe77w Jun. 24 at 3:20 PM

$ITOS Concentra in so I would not be surprised with a cash offer plus CVR, just speculation.

0 · Reply

Count__Stockula Jun. 23 at 4:21 AM

$ITOS hear the news last week? Annual shareholder meeting was held. More news coming this week. 😁

0 · Reply

Count__Stockula Jun. 14 at 12:59 PM

$ITOS news coming this week.

0 · Reply

bullwink Jun. 12 at 5:41 PM

$ITOS Is management going to do anything about strategic alterbatives and preserve shareholder capital or just smoke and mirror announcement weeks ago?

0 · Reply

Count__Stockula Jun. 11 at 6:22 AM

$ITOS should be asking whos been buying up shares and why.

0 · Reply

nico10 Jun. 10 at 9:51 AM

$ITOS insiders are selling big...

0 · Reply

nico10 Jun. 9 at 5:51 PM

$ITOS what is the future for this stock? In the last week it didnt moove

0 · Reply

Count__Stockula Jun. 3 at 5:49 PM

$ITOS news soon. Easy buy and wait. Some know and are keeping it to themselves.

0 · Reply

WillisC May. 29 at 7:03 PM

$ITOS Question: this company has $625 million in assets. Where did they get that money? Investors? Loans? Share dilution. They only have 30 million shares. So I don't think they could have raise $ through share dilution. No banks or investors in line for their money? hummmm. How would money just appear....

1 · Reply

TeresaTrades May. 29 at 6:07 PM

Heavy options volume $BIRK $VEEV $ITOS $GRND $EU

0 · Reply

joe77w May. 29 at 4:47 AM

$ITOS 120 mln should be burnt in order to cover Q2/Q3 operating exp plus restructuring costs, legal and adm fees. I dont know how much can be worth asset for sale, current pps fair imo. Too much uncertainty about cash expenditure and distributions. I dont know how much could be worth the compounds for sale.

0 · Reply

EddieH2020 May. 29 at 1:47 AM

$SGMO Could learn a thing from $ITOS PR today

0 · Reply

WillisC May. 28 at 10:30 PM

$ITOS any liabilities, closing applications, fees, attorneys etc... I wonder how much will get after all.

0 · Reply

CHItraders May. 28 at 9:27 PM

RECAP 5/28 +Pos Comments: $TBN + Northland RECAP 5/28 -Neg Comments: $TEM - Spruce Pt $MTAL - Scotiabank $ITOS -Wedbush $AZUL - JPM

0 · Reply

OpenOutcrier May. 28 at 8:02 PM

RECAP 5/28 +Pos Comments: $TBN + Northland RECAP 5/28 -Neg Comments: $TEM - Spruce Pt $MTAL - Scotiabank $ITOS -Wedbush $AZUL - JPM Live Breaking trading news www.openoutcrier.com

0 · Reply

StocktwitsNews May. 28 at 3:37 PM

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’ $ITOS $GSK $VTI https://stocktwits.com/news/equity/markets/iteos-therapeutics-winds-down-operations/ch0oNauRbsS

0 · Reply

BullDriven May. 28 at 2:58 PM

$ITOS Wells Fargo valuation also $12

0 · Reply

BullDriven May. 28 at 2:37 PM

$ITOS no more cash burn. Worth more selling it off than keeping it going

0 · Reply

Lukey63 May. 28 at 2:27 PM

$ITOS after expenses the liquidation value should be $12+ max. Some upside here possibly

0 · Reply

JarvisFlow May. 28 at 2:11 PM

Wedbush updates rating for ITeos Therapeutics ( $ITOS ) to Neutral, target set at 10 → 12.

0 · Reply

Market Cap	393.84M
Revenue (ttm)	35.00M
Net Income (ttm)	-134.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-384.03%
Debt to Equity Ratio	0.00

Volume	1,116,100
Avg Vol	1,584,458
Day's Range	N/A - N/A
Shares Out	38.27M
Stochastic %K	88%
Beta	1.49
Analysts	Sell
Price Target	$11.75